Navigation Links
Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
Date:2/11/2008

zation of novel therapeutics for cancer. The Company's lead product, MGCD0103, is an oral isotype-selective HDAC inhibitor presently in multiple clinical trials for solid tumors and hematological malignancies, including Phase II monotherapy and Phase I and Phase II combination trials with Vidaza(R), Gemzar(R) and Taxotere(R). MGCD265 is an oral kinase inhibitor targeting the c-Met, Tie-2, Ron and VEGF receptor tyrosine kinases. In addition, MethylGene's preclinical programs include: MGCD290 an HDAC inhibitor in combination with azoles for fungal infections and a sirtuins program for cancer. MethylGene's development and commercialization partners include Pharmion Corporation, Taiho Pharmaceutical and EnVivo Pharmaceuticals. Please visit our website at http://www.methylgene.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release contains forward-looking statements relating to MGCD0103, which express the current beliefs and expectations of management. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause Pharmion's future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include, but are not limited to, the potential failure of MGCD0103, to demonstrate safety and efficacy in clinical and non-clinical testing; the ability to complete regulatory submissions and gain regulatory approvals in a timely manner; the ability to initiate and complete trials at the referenced times; the impact of competition from other products under development by Pharmion's competitors; the uncertainty of the regulatory environment and changes in the health policies of various countries; acceptance and demand for new pharmaceutical pr
'/>"/>

SOURCE Pharmion Corporation; MethylGene Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
2. Pharmion and MethylGene Initiate Phase One Combination Clinical Trial with MGCD0103 and Taxotere(R) in Patients with Solid Tumors
3. Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
4. Pharmion and MethylGene Report Preliminary MGCD0103 Clinical Data at the 2007 AACR-NCI-EORTC International Conference
5. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
6. Pharmion and MethylGene Start Phase 2 Combination Clinical Trial With MGCD0103 and Vidaza(R) in Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
7. Pharmion Submits European Marketing Authorization Application (MAA) for Vidaza(R) in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
8. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... -- Eli Lilly and Company (NYSE: LLY ... in genetically engineered mice examining combination therapy with ... and beta-secretase inhibitor BACE (LY2811376). Data results found ... clumps of amyloid-beta protein in the brain – ... Alzheimer,s disease (AD) – than use of one ...
(Date:7/11/2014)... , July 11, 2014  Rock Creek Pharmaceuticals, Inc. ... today announced that the Food and Drug Administration ("FDA"), ... comments on RCP,s Investigational New Drug ("IND") application before ... in the US. Dr. Chris Chapman ... and comments on our IND. When we receive the ...
(Date:7/11/2014)... 2014  Kindred Hospital Houston Northwest, with Wound ... of its new outpatient wound healing center.  The ... with chronic, hard to heal wounds. Chronic wounds ... amputation, lower leg wounds related to blood flow ... traumatic injury wounds which are complex and demonstrate ...
Breaking Medicine Technology:New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3Rock Creek Pharmaceuticals Issues Update On US Investigational New Drug Application 2Kindred Hospital Houston Northwest, With Wound Care Specialists, Opens Outpatient Wound Healing And Hyperbaric Center 2
... The board of directors of Hospira, Inc. (NYSE: ... today announced that Christopher B. Begley, chairman and chief executive ... CEO position after more than six years of dedicated service. ... He will then remain an employee of the company as ...
... Amsterdam Next April 2011 -- AMSTERDAM, August 20, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:Hospira Announces CEO Succession Plan 2Hospira Announces CEO Succession Plan 3Hospira Announces CEO Succession Plan 4Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 2Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 3Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 4Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 5Pharma and Food Thought Leaders Set to Converge in Amsterdam Next April 2011 6
(Date:7/13/2014)... (PRWEB) July 13, 2014 Manchester United ... with the 2014 Guinness International Champions Cup. The 2014 ... soil each year because of the talent of it brings ... and AS Roma will compete in the 2014 event spread ... July 24 with a game between Olympiacos and Milan and ...
(Date:7/13/2014)... An editorial published today in The Lancet ... into consideration the long term neurological problems that ... the most common form of sports-related traumatic brain ... concussions may include dementia, amyotrophic lateral sclerosis, and ... what is perhaps more concerning, is that even ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Intraocular Lens ... and Forecast 2013 - 2019 , Intraocular lens (IOL) ... from myopia or cataracts. The lenses are inserted inside ... cataract surgery intraocular lens replaces the focusing power of ... original crystalline lens to deliver the light focusing function ...
(Date:7/13/2014)... Recently, MillionaireCasket.com, a well-known casket manufacturer from China, has announced ... company’s chief executive officer has announced a new promotion for ... at discounted prices, from 15 to 26 percent off. , ... huge demand in the current market. We are excited to ... lot of high quality products for sale. Many of our ...
(Date:7/13/2014)... July 13, 2014 The report ... Molybdenum, Iron), Form (Chelated & Non Chelated), Application ... - Global Trends and Forecast to 2018” defines ... an analysis and forecasting of the global value ... the driving and restraining factors for the global ...
Breaking Medicine News(10 mins):Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 2Health News:Manchester United vs. AS Roma Tickets in Denver, CO at Sports Authority Field at Mile High: Ticket Down Slashes Ticket Prices on International Champions Cup in Denver 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Intraocular Lens (IOL) Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:Cheap Oak Caskets Recently Unveiled By China Casket Manufacturer MillionaireCasket.com 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 2Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 3Health News:Micronutrient Market Worth $6,474.6 Million by 2018 - A Report by MarketsandMarkets 4
... Specialties, Mfg. is pleased to announce the introduction of push-to-connect ... Mfg and designed with John Guest push-to-connect style fittings integrated ... offers versatility and customization for a variety of applications. ... ...
... Oct. 7 ProGenTech Limited, a life,sciences & ... CA,has signed a licensing agreement with Human Genetic ... gain access to key,hospital-acquired infection targets, payment terms ... the agreement, Human Genetic Signatures will develop,assays for ...
... for food-allergic kids and their parents. All kids want to join in ... they can…as long as they steer clear of the foods that pose ... ... EON) October 6, 2008 -- Enjoy Life Foods, the country,s leader ...
... VOLC ), a leader in the development, ... treatment of coronary and peripheral artery,disease, today announced ... Rancho Cordova to San Diego. The new corporate,headquarters ... San Diego and now,houses corporate executives, marketing, finance, ...
... The United States has,intervened in a lawsuit ... claims to Medicare arising from illegal kickbacks ... (DME) suppliers, the,Justice Department announced today. The ... (MediNet), GGNSC Holdings LLC,Golden Gate Ancillary LLC, ...
... presented at the American College of Gastroenterology Annual ... TAK-390MR resulted in higher healing rates than lansoprazole ... esophagitis (EE). TAK-390MR combines dexlansoprazole with a Dual ... separate releases of drug for extended duration of ...
Cached Medicine News:Health News:ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal 2Health News:ProGenTech Targets Clinical Diagnostics and Applied Sciences Markets with Human Genetic Signatures Deal 3Health News: Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween 2Health News: Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween 3Health News: Enjoy Life Foods Teams with AllergyMoms.com to Ensure Halloween Isn't 'Tricky' for Food-Allergic Kids and Families : Provides tips for being allergy-aware this Halloween 4Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 2Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 3Health News:Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego 4Health News:U.S. Intervenes in False Claims Act Suit Against McKesson Corp. and Golden Horizons Nursing Homes 2Health News:Takeda's investigational PPI TAK-390MR demonstrated higher healing rates compared to lansoprazole 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: